PL2121674T3 - Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV - Google Patents

Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV

Info

Publication number
PL2121674T3
PL2121674T3 PL08708576T PL08708576T PL2121674T3 PL 2121674 T3 PL2121674 T3 PL 2121674T3 PL 08708576 T PL08708576 T PL 08708576T PL 08708576 T PL08708576 T PL 08708576T PL 2121674 T3 PL2121674 T3 PL 2121674T3
Authority
PL
Poland
Prior art keywords
hcv
intermediates
preparing
processes
protease inhibitor
Prior art date
Application number
PL08708576T
Other languages
English (en)
Inventor
Andras Horvath
Dominique Paul Michel Depré
Dominic John Ormerod
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PL2121674T3 publication Critical patent/PL2121674T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/03—Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08708576T 2007-02-01 2008-02-01 Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV PL2121674T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07101571 2007-02-01
PCT/EP2008/051269 WO2008092955A1 (en) 2007-02-01 2008-02-01 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
EP08708576A EP2121674B1 (en) 2007-02-01 2008-02-01 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
PL2121674T3 true PL2121674T3 (pl) 2010-10-29

Family

ID=38337997

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08708576T PL2121674T3 (pl) 2007-02-01 2008-02-01 Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV

Country Status (25)

Country Link
US (2) US8212043B2 (pl)
EP (1) EP2121674B1 (pl)
JP (1) JP5563830B2 (pl)
KR (1) KR101598135B1 (pl)
CN (3) CN105111200A (pl)
AR (1) AR065137A1 (pl)
AT (1) ATE467630T1 (pl)
AU (1) AU2008209697B2 (pl)
BR (1) BRPI0806853B1 (pl)
CA (1) CA2677173C (pl)
CL (1) CL2008000322A1 (pl)
CY (1) CY1110893T1 (pl)
DE (1) DE602008001251D1 (pl)
DK (1) DK2121674T3 (pl)
ES (1) ES2345857T3 (pl)
HK (1) HK1217952A1 (pl)
HR (1) HRP20100429T1 (pl)
IL (1) IL199276A (pl)
MX (1) MX2009008271A (pl)
PL (1) PL2121674T3 (pl)
PT (1) PT2121674E (pl)
RU (1) RU2483067C2 (pl)
SI (1) SI2121674T1 (pl)
TW (1) TWI455936B (pl)
WO (1) WO2008092955A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL2121674T3 (pl) * 2007-02-01 2010-10-29 Janssen Sciences Ireland Uc Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
BRPI0923393B1 (pt) * 2008-12-23 2018-06-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso".
MX340792B (es) * 2009-02-27 2016-07-25 Ortho-Mcneil-Janssen Pharmaceuticals Inc * Sal amorfa de un inhibidor macrociclico de virus de hepatitis c.
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
KR101781789B1 (ko) 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
KR20130034012A (ko) * 2010-03-16 2013-04-04 얀센 파마슈티칼즈, 인코포레이티드 Ｈｃｖ의 마크로사이클릭 프로테아제 저해제를 제조하기 위한 방법 및 중간체
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
EA201490675A1 (ru) * 2011-09-22 2014-08-29 Янссен Фармасьютикалз, Инк. Способы и промежуточные соединения для получения макроциклического ингибитора протеазы hcv
HRP20180591T1 (hr) 2012-03-01 2018-05-18 Array Biopharma, Inc. Inhibitori kinaze serina ili treonina
WO2013137330A1 (ja) * 2012-03-14 2013-09-19 積水メディカル株式会社 光学活性２－ビニルシクロプロパン－１，１－ジカルボン酸エステルの製造法
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105237528B (zh) * 2014-06-09 2019-06-04 深圳翰宇药业股份有限公司 Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法
CN105175406B (zh) * 2014-06-09 2019-06-04 深圳翰宇药业股份有限公司 Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
CN107098805A (zh) * 2017-05-17 2017-08-29 盐城同泰化工科技有限公司 一种4‑环戊酮‑1，2‑二甲酸的制备方法
CN115850070B (zh) * 2022-12-13 2025-11-21 渭南高新区海泰新型电子材料有限责任公司 一种环己烷二羧酸单酯类化合物的合成方法
CN118652175A (zh) * 2024-08-21 2024-09-17 兰州大学 一种磷酸芳香酯催化ε-己内酯接枝丙烯酸羟乙酯类化合物的方法
CN118652174B (zh) * 2024-08-21 2025-03-14 兰州大学 一种酸性树脂催化ε-己内酯接枝丙烯酸羟乙酯类化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
KR20120090077A (ko) * 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PL2121674T3 (pl) * 2007-02-01 2010-10-29 Janssen Sciences Ireland Uc Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV

Also Published As

Publication number Publication date
HK1217952A1 (zh) 2017-01-27
CN101600713A (zh) 2009-12-09
EP2121674B1 (en) 2010-05-12
HK1137442A1 (en) 2010-07-30
TW200846346A (en) 2008-12-01
CY1110893T1 (el) 2015-06-10
CL2008000322A1 (es) 2008-09-05
US20120238746A1 (en) 2012-09-20
HK1186458A1 (zh) 2014-03-14
IL199276A (en) 2014-12-31
AU2008209697B2 (en) 2014-02-20
BRPI0806853B1 (pt) 2018-03-20
US8722892B2 (en) 2014-05-13
ATE467630T1 (de) 2010-05-15
SI2121674T1 (sl) 2010-09-30
JP2010517972A (ja) 2010-05-27
HRP20100429T1 (hr) 2010-09-30
BRPI0806853A2 (pt) 2014-04-29
KR20090107038A (ko) 2009-10-12
CA2677173A1 (en) 2008-08-07
CN103145699A (zh) 2013-06-12
CN105111200A (zh) 2015-12-02
WO2008092955A1 (en) 2008-08-07
RU2483067C2 (ru) 2013-05-27
US8212043B2 (en) 2012-07-03
DK2121674T3 (da) 2010-09-13
ES2345857T3 (es) 2010-10-04
PT2121674E (pt) 2010-09-03
AU2008209697A1 (en) 2008-08-07
AR065137A1 (es) 2009-05-20
KR101598135B1 (ko) 2016-02-26
TWI455936B (zh) 2014-10-11
CN101600713B (zh) 2014-11-12
RU2009132673A (ru) 2011-03-10
DE602008001251D1 (de) 2010-06-24
JP5563830B2 (ja) 2014-07-30
US20100041889A1 (en) 2010-02-18
EP2121674A1 (en) 2009-11-25
CA2677173C (en) 2017-12-12
CN103145699B (zh) 2015-09-09
MX2009008271A (es) 2009-08-12

Similar Documents

Publication Publication Date Title
SI2121674T1 (sl) Postopki in intermediati za pripravo makrocikličnega proteaznega inhibitorja HCV
IL213246A0 (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
ZA200905377B (en) Polymorphic forms of a macrocyclic inhibitor of HCV
IL195515A0 (en) Macrocyclic oximyl hepatitis c protease inhibitors
IL219123A0 (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
HUS1500020I1 (hu) Makrociklusos Hepatitis C szerin proteáz inhibitorok
EP2219454A4 (en) HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
EP2224920A4 (en) PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
ZA201202631B (en) Hcv protease inhibitors
EP2224801A4 (en) MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE
EP2432318A4 (en) NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
AP2703A (en) A method of diagnosis and kit therefor
IL221242A0 (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
IL231024A0 (en) Processes and intermediates for the preparation of a macrocyclic protease inhibitor for hepatitis c virus
ZA200810235B (en) Macrocyclic oximyl hepatitis C protease inhibitors
SG2014011258A (en) Hcv protease inhibitors